Table 1: Summary of autologous blood transfusion (ABT) studies examining changes in aerobic power and endurance performance following ABT

Gullbring et al. [1]

6 M, UT, 34 ± 8

No control group

530–689^{R, 1}

N/A

PWC/TTE cycling (N/A)

4%

Robinson et al. [20]

6 M, UT, 26 ± 6

No control group

1000–1200^{R, 2}

↔

N/A

N/A

Ekblom et al. [13]

7 M, WT, 24 ± 1

No control group

800–1200^{R, 4}

↑ 9% (1)

TTE running (~ 5 min)

↑ 23% (1)

Williams et al. [21]

20 M, MT-WT, 22 ± 4

Double-blind, placebo-controlled

500^{R, 3}

N/A

TTE running (~ 10 min)

↔

Von Rost et al. [8]

6 M, MT, N/A

Controlled

900^{R, 3–4}

↑ 6%

TTE running (~ 5 min)

↑ 37%

Ekblom et al. [22]

5 M, WT, 23–31

No control group

800^{R, 5}

↑ 8%

N/A

N/A

Bell et al. [23]

15 M, MT, 18–24

Controlled

500^{R, 3}

↔

TTE cycling (~ 15 min)

↔

Kots et al. [16]

10 M, UT-WT, 22–32

No control group

500^{R, 3}

↔

PWC/TTE cycling (~ 10 min)

↑ 40%

Williams et al. [24]

16 M, WT, 32 ± 7

Double-blind, placebo-controlled

460^{F, 3}

N/A

TTE running (~ 45 min)

↔

Buick et al. [10]

11 M, WT, 21 ± 3

Double-blind, placebo-controlled, crossover

900^{F, 7}

↑ 5%

TTE running (7–10 min)

↑ 31–35%

Williams et al. [14]

12 M, WT, 33 ± 6

Double-blind, placebo-controlled, crossover

920^{F, 7}

N/A

TT running (5 miles)

↑ 3%

Thomson et al. [25]

4 M, MT-WT, 23 ± 1

No control group

1000^{F, 12}

↑ 12%

N/A

N/A

Thomson et al. [26]

4 M, MT-WT, 23 ± 1

No control group

1000^{F, 12}

↑ 13%

N/A

N/A

Kanstrup and Ekblom [11]

5 M, WT, 25 ± 4

No control group

900^{R, 5}

↑ 7%

TTE running (5–6 min)

↑ 24%

Robertson et al. [5]

9 W, UT-MT, 23 ± 2

Single-blind, placebo-controlled, crossover

475^{F, 9}

↑ 10%

PWC cycling

↑ 23%

Celsing et al. [27]

9 M, WT, 29 ± 2

No control group

3500^{R, F, 1–8}

↑ 19%

N/A

N/A

Spriet et al. [28]

4 M, WT, 25 ± 1

No control group

1350^{F, 9–11}

↑ 7%

N/A

N/A

Muza et al. [29]

12 M, MT-WT, 27 ± 6

Double-blind, placebo-controlled

600^{F, 6}

↑ 11%

N/A

N/A

Berglund and Hemmingsson [2, 30]

11 M, 1 W, WT, 19–35

Single-blind, placebo-controlled

1350 ^{R, 4}

N/A

TT cross-country skiing (15 km)

↑ 5%

Brien and Simon [9]

6 M, WT, 24 ± 5

Double-blind, placebo-controlled, crossover

900^{F, 11}

N/A

TT running (10 km)

↑ 3%

Celsing et al. [31]

8 M, UT-MT, 28 ± 3

Controlled

2250^{F, 5–7}

↑ 7%

N/A

N/A

Sawka et al. [32]

9 M, MT, 30 ± 7

Double-blind, placebo-controlled

600^{F, N/A}

↑ 11%

N/A

N/A

Ekblom and Berglund [12]

15 M, MT-WT, 27 ± 3

No control group

1350^{F. 8}

↑ 8%

TTE running (7–9 min)

↑ 16%

Turner et al. [15]

7 M, MT, 26 ± 3

No control group

900^{F, 8–12}

↑ 6%

TT cycling (30 min)

↑ 5%

Ziegler et al. [6]

8 M, UT-WT, 33 ± 2

No control group

450^{R, 4}

↑ 5%

TT running (3 km)

↑ 5%

Malm et al. [3]

17 M, MT-WT, 34 ± 8

Placebo-controlled

900^{F, 15–16}

↑ 12%

TTE running (6–7 min)

↑ 17%

Bennett-Guerrero et al. [4]

4 M, UT-MT, 34 ± 5 1 week, 29 ± 7 6 weeks

No control group

900^{R, 1 or 6}

↑ 9% 1 week, ↑ 2% 6 weeks

TTE cycling (12–16 min)

↑ 8% 1 week, ↓3% 6 weeks

Bejder et al. [7]

9 M, WT, 29 ± 5

Double-blind, placebo-controlled, crossover

225^{R, 4}

675^{R, 4}

N/A

↔

TT cycling (650 kcal)

↑ 4%

↑ 5%